Literature DB >> 15102772

Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Claudia Carvalho-Queiroz1, Rosemary Cook, Ching C Wang, Rodrigo Correa-Oliveira, Nicola A Bailey, Nejat K Egilmez, Edith Mathiowitz, Philip T LoVerde.   

Abstract

Schistosoma mansoni, an intravascular parasite, has evolved a number of immune evasion mechanisms to establish itself in the host, such as antioxidant enzymes. Our laboratory has demonstrated that the highest levels of certain antioxidant enzymes are found in adult worms, which are the least susceptible to immune killing. Vaccination of mice with naked DNA constructs containing the gene encoding Cu/Zn cytosolic superoxide dismutase (SmCT-SOD) showed significant levels of protection compared to a control group, and our data demonstrate that the adult worms are a target of the immune response that confers resistance in SmCT-SOD DNA-vaccinated mice. Because SmCT-SOD shows significant identity with the human homologue, we evaluated the reactivity of anti-SmCT-SOD antibodies derived from SmCT-SOD-immunized mice and rabbits and from S. mansoni-infected individuals to human superoxide dismutase (hSOD) and SmCT-SOD parasite-specific peptides to assess the potential for autoimmune responses from immunization with the recombinant molecule. In addition, we evaluated the ability of various SmCT-SOD adjuvant-delivered immunizations to induce cross-reactive antibodies. Both mouse and rabbit antibodies generated against SmCT-SOD recognized the denatured form of hSOD. The same antibodies did not recognize nondenatured hSOD. Sera from infected individuals with different clinical forms of schistosomiasis recognized SmCT-SOD but not hSOD. Antibodies from mice immunized with different SmCT-SOD-containing formulations of both DNA and protein were able to recognize SmCT-SOD-derived peptides but not soluble hSOD. All together, these findings serve as a basis for developing a subunit vaccine against schistosomiasis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102772      PMCID: PMC387882          DOI: 10.1128/IAI.72.5.2635-2647.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  68 in total

Review 1.  Recent developments in adjuvants for vaccines against infectious diseases.

Authors:  D T O'Hagan; M L MacKichan; M Singh
Journal:  Biomol Eng       Date:  2001-10-15

2.  Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase.

Authors:  Hatem Tallima; Mona Montash; Pavel Veprek; Jiri Velek; Jan Jezek; Rashika El Ridi
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

Review 3.  Effector functions of eosinophils in schistosomiasis.

Authors:  M Capron; A Capron
Journal:  Mem Inst Oswaldo Cruz       Date:  1992       Impact factor: 2.743

4.  Expression and characterization of glutathione peroxidase activity in the human blood fluke Schistosoma mansoni.

Authors:  H Mei; A Thakur; J Schwartz; P T Lo Verde
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

Review 5.  Molecular mimicry: parasite evasion and host defense.

Authors:  R T Damian
Journal:  Curr Top Microbiol Immunol       Date:  1989       Impact factor: 4.291

6.  Schistosoma mansoni: levels of antioxidants and resistance to oxidants increase during development.

Authors:  B Nare; J M Smith; R K Prichard
Journal:  Exp Parasitol       Date:  1990-05       Impact factor: 2.011

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 8.  Immune effector role of macrophages in experimental schistosomiasis mansoni.

Authors:  S L James; D L Boros
Journal:  Immunol Ser       Date:  1994

9.  Resistance to Schistosoma mansoni in humans: influence of the IgE/IgG4 balance and IgG2 in immunity to reinfection after chemotherapy.

Authors:  C E Demeure; P Rihet; L Abel; M Ouattara; A Bourgois; A J Dessein
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

10.  Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium.

Authors:  P Hagan; U J Blumenthal; D Dunn; A J Simpson; H A Wilkins
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

View more
  8 in total

Review 1.  The redox biology of schistosome parasites and applications for drug development.

Authors:  Hsin-Hung Huang; Coraline Rigouin; David L Williams
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

2.  Mapping of B-cell epitopes on a novel 11.5-kilodalton Fasciola hepatica-Schistosoma mansoni cross-reactive antigen belonging to a member of the F. hepatica saposin-like protein family.

Authors:  Daricel Torres; Ana M Espino
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

3.  Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage.

Authors:  Rosemary M Cook; Claudia Carvalho-Queiroz; Gregory Wilding; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

4.  Functional expression and characterization of a cytosolic copper/zinc-superoxide dismutase of Spirometra erinacei.

Authors:  Ai-Hua Li; Byoung-Kuk Na; Sung-Kyu Ahn; Shin-Hyeong Cho; Jhang-Ho Pak; Yun-Kyu Park; Tong-Soo Kim
Journal:  Parasitol Res       Date:  2010-02       Impact factor: 2.289

Review 5.  Antigen Mimicry between Infectious Agents and Self or Environmental Antigens May Lead to Long-Term Regulation of Inflammation.

Authors:  Lain Pontes-de-Carvalho; Jose Mengel; Camila A Figueiredo; Neuza M Alcântara-Neves
Journal:  Front Immunol       Date:  2013-10-08       Impact factor: 7.561

6.  Protective Potential of Antioxidant Enzymes as Vaccines for Schistosomiasis in a Non-Human Primate Model.

Authors:  Claudia Carvalho-Queiroz; Ruth Nyakundi; Paul Ogongo; Hitler Rikoi; Nejat K Egilmez; Idle O Farah; Thomas M Kariuki; Philip T LoVerde
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

Review 7.  Kicking in the Guts: Schistosoma mansoni Digestive Tract Proteins are Potential Candidates for Vaccine Development.

Authors:  Barbara Castro-Pimentel Figueiredo; Natasha Delaqua Ricci; Natan Raimundo Gonçalves de Assis; Suellen Batistoni de Morais; Cristina Toscano Fonseca; Sergio Costa Oliveira
Journal:  Front Immunol       Date:  2015-01-28       Impact factor: 7.561

8.  Known Allergen Structures Predict Schistosoma mansoni IgE-Binding Antigens in Human Infection.

Authors:  Edward J Farnell; Nidhi Tyagi; Stephanie Ryan; Iain W Chalmers; Angela Pinot de Moira; Frances M Jones; Jakub Wawrzyniak; Colin M Fitzsimmons; Edridah M Tukahebwa; Nicholas Furnham; Rick M Maizels; David W Dunne
Journal:  Front Immunol       Date:  2015-02-03       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.